{"id":"nct:NCT03552757","kind":"trial","title":"Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity","authors":["Novo Nordisk A/S"],"author_count":1,"year":2018,"published":"2018-06-12","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT03552757","source_url":"https://clinicaltrials.gov/study/NCT03552757","archive_url":"https://space-kitty.com/papers/nct:NCT03552757","updated":"2021-11-09","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking \"dummy\" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk of type 2 diabetes. Therefore, weight loss has shown to have a beneficial impact on the blood sugar levels. The participant will either get semaglutide or \"dummy\" medicine - which treatment the participant get is decided by chance. The participant will need to take 2 injections at the same time once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 1.5 years","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Obesity","Overweight"],"details":{"acronym":"STEP 2","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1210,"sponsor":"Novo Nordisk A/S","conditions":["Obesity","Overweight"],"interventions":["DRUG: Semaglutide 1.0 mg","DRUG: Semaglutide 2.4 mg","DRUG: Placebo I (Semaglutide)","DRUG: Placebo II (Semaglutide)"],"start_date":"2018-06-04","start_date_type":"ACTUAL","primary_completion_date":"2020-03-24","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}